CapsoVision (NASDAQ:CV) Trading Down 1.4% – Should You Sell?

CapsoVision, Inc. (NASDAQ:CV) shares were down 1.4% during mid-day trading on Thursday . The company traded as low as $6.91 and last traded at $6.99. Approximately 120,993 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 127,416 shares. The stock had previously closed at $7.09.

Analysts Set New Price Targets

Separately, Benchmark decreased their price target on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

CapsoVision Price Performance

The business has a 50-day simple moving average of $6.71 and a 200 day simple moving average of $7.05. The firm has a market cap of $349.22 million and a PE ratio of -2.99.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter. The company had revenue of $2.79 million during the quarter.

Institutional Trading of CapsoVision

A number of hedge funds and other institutional investors have recently modified their holdings of CV. Bank of America Corp DE raised its position in shares of CapsoVision by 528.9% during the 1st quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock valued at $162,000 after purchasing an additional 18,702 shares during the period. Bank of New York Mellon Corp purchased a new stake in CapsoVision in the 1st quarter worth $359,000. Virtu Financial LLC bought a new stake in CapsoVision during the fourth quarter valued at about $128,000. Millennium Management LLC purchased a new position in shares of CapsoVision in the fourth quarter valued at about $163,000. Finally, State Street Corp boosted its stake in shares of CapsoVision by 340.7% in the fourth quarter. State Street Corp now owns 85,929 shares of the company’s stock worth $919,000 after acquiring an additional 66,429 shares during the period.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.